Share Price and Basic Stock Data
Last Updated: December 19, 2025, 8:17 pm
| PEG Ratio | -6.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Camlin Fine Sciences Ltd operates in the specialty chemicals sector, focusing on a range of products including food additives and industrial chemicals. As of its latest financial reports, the company’s revenue for FY 2025 stood at ₹1,667 Cr, a modest increase from ₹1,454 Cr in FY 2024. However, the revenue growth has not been linear; quarterly sales fluctuated recently, with a peak of ₹483 Cr in September 2022, but have since shown a declining trend, with the most recent quarter recording ₹406 Cr in September 2023. This volatility raises concerns about consistent demand and operational stability. Additionally, the company’s operating profit margin (OPM) has remained relatively low, reported at just 13% in FY 2025, compared to a more robust 16% in FY 2021. This indicates that while the company has managed to grow its top line, it faces challenges in translating that into sustainable profitability.
Profitability and Efficiency Metrics
Profitability metrics for Camlin Fine Sciences present a mixed picture. The company reported a net loss of ₹158 Cr for FY 2025, a significant drop from a profit of ₹40 Cr in FY 2023. This decline in profitability is alarming, especially given that the company had previously enjoyed positive earnings momentum. The operating profit has also been under pressure, with the OPM declining from 13% in FY 2024 to 10% in FY 2025. Additionally, the interest coverage ratio (ICR) stood at 2.23x, which while above 2, indicates that while the company can cover its interest obligations, the buffer is not substantial. Furthermore, the cash conversion cycle (CCC) of 143 days suggests that the company is taking longer to convert its investments in inventory and receivables into cash, which can strain liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
Camlin’s balance sheet reflects a mix of strengths and weaknesses. The company has total borrowings of ₹681 Cr against reserves of ₹883 Cr, indicating a relatively comfortable leverage position with a debt-to-equity ratio of 0.71x. This suggests that while the company has taken on debt, it is not excessively leveraged, which could be a positive sign for long-term sustainability. However, the return on equity (ROE) has dipped to 15%, down from 6.92% in FY 2023, signaling reduced profitability relative to shareholder equity. The current ratio remains healthy at 1.40x, suggesting that the company is in a position to meet its short-term liabilities. However, the book value per share has decreased slightly to ₹47.81, raising questions about the preservation of shareholder value in light of recent losses.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Camlin Fine Sciences reveals a significant shift in ownership dynamics. Promoter holdings have seen a remarkable increase, from 17.64% in March 2023 to 48.03% in September 2023. This could indicate a strong commitment from the management to stabilize and guide the company through turbulent times. However, institutional investors have reduced their stakes, with foreign institutional investors (FIIs) decreasing from 10.18% to just 1.61% over the same period. Domestic institutional investors (DIIs) also showed a decline. The public shareholding now stands at 42.04%, a significant reduction from previous levels. This decline in institutional confidence could be a red flag for retail investors, suggesting that larger players are cautious about the company’s prospects in light of its financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Camlin Fine Sciences faces a challenging environment marked by operational volatility and profitability concerns. The recent dip in revenue and net profit highlights the risks associated with fluctuating demand and rising operational costs. Investors should be cautious; the company’s high P/E ratio of 170 suggests that the market has high expectations for future growth, which may not be met given the current financial trajectory. Additionally, the prolonged cash conversion cycle could exacerbate liquidity issues if not addressed. However, the increase in promoter holdings may provide some reassurance about management’s commitment to turnaround strategies. Investors should closely monitor the company’s ability to stabilize its revenue streams and improve operational efficiency in the coming quarters, as these factors will be critical in determining whether Camlin Fine Sciences can regain its footing and restore investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 395 Cr. | 42.9 | 83.5/41.2 | 24.5 | 20.5 | 0.93 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.2 Cr. | 59.5 | 94.0/56.0 | 14.0 | 89.6 | 1.68 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.6 Cr. | 729 | 956/600 | 22.8 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,399 Cr. | 75.0 | 111/74.1 | 22.5 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 638 Cr. | 258 | 416/241 | 22.9 | 93.8 | 0.97 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,811.96 Cr | 727.68 | 74.82 | 183.02 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 483 | 388 | 427 | 420 | 406 | 386 | 377 | 381 | 423 | 431 | 437 | 424 |
| Expenses | 337 | 428 | 338 | 383 | 381 | 381 | 363 | 345 | 352 | 380 | 375 | 378 | 405 |
| Operating Profit | 47 | 55 | 50 | 44 | 39 | 25 | 23 | 31 | 29 | 43 | 56 | 59 | 19 |
| OPM % | 12% | 11% | 13% | 10% | 9% | 6% | 6% | 8% | 8% | 10% | 13% | 14% | 4% |
| Other Income | 1 | 3 | 10 | -8 | 6 | 2 | 2 | -96 | -15 | -138 | -8 | -17 | 3 |
| Interest | 19 | 18 | 12 | 10 | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 16 | 16 |
| Depreciation | 14 | 14 | 16 | 18 | 19 | 19 | 21 | 13 | 15 | 21 | 14 | 18 | 17 |
| Profit before tax | 15 | 26 | 32 | 8 | 16 | -12 | -10 | -94 | -23 | -142 | -0 | 8 | -11 |
| Tax % | 75% | 61% | 28% | 59% | 25% | 72% | 47% | -13% | 48% | -18% | 2,164% | 99% | -0% |
| Net Profit | 4 | 10 | 23 | 3 | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 |
| EPS in Rs | 0.33 | 0.74 | 1.36 | 0.52 | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 |
Last Updated: August 20, 2025, 12:30 pm
Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 424.00 Cr.. The value appears to be declining and may need further review. It has decreased from 437.00 Cr. (Mar 2025) to 424.00 Cr., marking a decrease of 13.00 Cr..
- For Expenses, as of Jun 2025, the value is 405.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2025) to 405.00 Cr., marking an increase of 27.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 40.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -17.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 20.00 Cr..
- For Interest, as of Jun 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 19.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 99.00% (Mar 2025) to 0.00%, marking a decrease of 99.00%.
- For Net Profit, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.53. The value appears to be declining and may need further review. It has decreased from -0.04 (Mar 2025) to -0.53, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,667 | 1,752 |
| Expenses | 446 | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,468 | 1,284 | 1,447 | 1,584 |
| Operating Profit | 63 | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 213 | 170 | 220 | 167 |
| OPM % | 12% | 15% | 19% | 6% | 2% | 8% | 13% | 16% | 11% | 13% | 12% | 13% | 10% |
| Other Income | 9 | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -203 | -26 |
| Interest | 25 | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 66 | 70 | 111 | 85 |
| Depreciation | 12 | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 64 | 69 |
| Profit before tax | 35 | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -158 | -12 |
| Tax % | 18% | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | 0% | |
| Net Profit | 29 | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | -33 |
| EPS in Rs | 2.71 | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | -1.55 |
| Dividend Payout % | 12% | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.66% | -34.55% | -111.11% | -500.00% | 112.50% | 900.00% | 116.67% | -7.69% | -33.33% | -362.50% | -50.48% |
| Change in YoY Net Profit Growth (%) | 0.00% | -124.20% | -76.57% | -388.89% | 612.50% | 787.50% | -783.33% | -124.36% | -25.64% | -329.17% | 312.02% |
Camlin Fine Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 223% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -7% |
| Last Year: | -15% |
Last Updated: September 5, 2025, 1:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 84 | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 871 |
| Borrowings | 150 | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 681 | 672 |
| Other Liabilities | 126 | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 454 | 476 |
| Total Liabilities | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
| Fixed Assets | 83 | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 700 |
| CWIP | 22 | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 15 |
| Investments | 1 | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 69 |
| Other Assets | 262 | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,262 | 1,253 |
| Total Assets | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.00 Cr..
- For Reserves, as of Sep 2025, the value is 871.00 Cr.. The value appears to be declining and may need further review. It has decreased from 883.00 Cr. (Mar 2025) to 871.00 Cr., marking a decrease of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 672.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 681.00 Cr. (Mar 2025) to 672.00 Cr., marking a decrease of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 476.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2025) to 476.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 700.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Mar 2025) to 700.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 69.00 Cr., marking an increase of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,262.00 Cr. (Mar 2025) to 1,253.00 Cr., marking a decrease of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
Notably, the Reserves (871.00 Cr.) exceed the Borrowings (672.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -87.00 | -76.00 | -88.00 | -299.00 | -357.00 | -388.00 | -404.00 | -363.00 | -488.00 | -588.00 | -513.00 | -461.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 72 |
| Inventory Days | 145 | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 233 |
| Days Payable | 132 | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 162 |
| Cash Conversion Cycle | 85 | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 143 |
| Working Capital Days | -4 | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 35 |
| ROCE % | 28% | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Commodities Fund | 4,624,431 | 2.41 | 76.27 | 2,957,188 | 2025-12-15 01:00:05 | 56.38% |
| Franklin India Opportunities Fund | 3,135,785 | 0.62 | 51.72 | 2,764,166 | 2025-12-15 01:00:05 | 13.44% |
| ICICI Prudential Multicap Fund | 2,665,909 | 0.27 | 43.97 | 1,802,309 | 2025-12-15 01:00:05 | 47.92% |
| JM Aggressive Hybrid Fund | 554,131 | 1.13 | 9.14 | 704,131 | 2025-12-15 01:00:05 | -21.3% |
| ICICI Prudential Retirement Fund - Pure Equity | 313,993 | 0.33 | 5.18 | N/A | N/A | N/A |
| ICICI Prudential MidCap Fund | 82,527 | 0.02 | 1.36 | N/A | N/A | N/A |
| ICICI Prudential Business Cycle Fund | 50,000 | 0.01 | 0.82 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -8.03 | -5.58 | 3.45 | 4.65 | 4.13 |
| Diluted EPS (Rs.) | -7.95 | -5.50 | 3.41 | 4.56 | 3.68 |
| Cash EPS (Rs.) | -5.04 | -1.57 | 6.51 | 7.42 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 47.81 | 48.29 | 48.18 | 43.26 | 47.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 47.81 | 50.97 | 52.25 | 48.52 | 55.67 |
| Revenue From Operations / Share (Rs.) | 88.68 | 96.32 | 107.04 | 89.95 | 93.11 |
| PBDIT / Share (Rs.) | 11.84 | 5.34 | 13.44 | 11.84 | 14.66 |
| PBIT / Share (Rs.) | 8.45 | 0.64 | 9.46 | 8.27 | 11.19 |
| PBT / Share (Rs.) | 2.61 | -5.93 | 5.12 | 5.99 | 8.24 |
| Net Profit / Share (Rs.) | -8.44 | -6.26 | 2.53 | 3.85 | 5.13 |
| NP After MI And SOA / Share (Rs.) | -7.40 | -5.54 | 3.32 | 3.87 | 4.00 |
| PBDIT Margin (%) | 13.35 | 5.54 | 12.55 | 13.16 | 15.74 |
| PBIT Margin (%) | 9.52 | 0.67 | 8.83 | 9.19 | 12.01 |
| PBT Margin (%) | 2.94 | -6.15 | 4.77 | 6.66 | 8.85 |
| Net Profit Margin (%) | -9.51 | -6.50 | 2.36 | 4.28 | 5.50 |
| NP After MI And SOA Margin (%) | -8.34 | -5.75 | 3.09 | 4.29 | 4.29 |
| Return on Networth / Equity (%) | -15.47 | -11.35 | 6.92 | 9.16 | 9.43 |
| Return on Capital Employeed (%) | 13.47 | 0.89 | 11.72 | 10.77 | 14.20 |
| Return On Assets (%) | -6.87 | -4.75 | 2.52 | 3.37 | 3.43 |
| Long Term Debt / Equity (X) | 0.29 | 0.40 | 0.54 | 0.58 | 0.50 |
| Total Debt / Equity (X) | 0.71 | 0.80 | 1.04 | 0.94 | 0.99 |
| Asset Turnover Ratio (%) | 0.83 | 0.80 | 0.46 | 0.48 | 0.52 |
| Current Ratio (X) | 1.40 | 1.37 | 1.37 | 1.50 | 1.66 |
| Quick Ratio (X) | 0.77 | 0.66 | 0.65 | 0.87 | 0.99 |
| Inventory Turnover Ratio (X) | 3.21 | 1.38 | 1.29 | 1.65 | 1.79 |
| Interest Coverage Ratio (X) | 2.23 | 1.48 | 3.61 | 5.20 | 4.98 |
| Interest Coverage Ratio (Post Tax) (X) | 1.59 | 0.08 | 1.85 | 2.69 | 2.74 |
| Enterprise Value (Cr.) | 3620.14 | 2050.95 | 2685.65 | 2687.50 | 2251.73 |
| EV / Net Operating Revenue (X) | 2.17 | 1.27 | 1.60 | 1.90 | 1.90 |
| EV / EBITDA (X) | 16.27 | 22.92 | 12.72 | 14.46 | 12.05 |
| MarketCap / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| Price / BV (X) | 3.51 | 1.83 | 2.66 | 3.31 | 3.30 |
| Price / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| EarningsYield | -0.04 | -0.06 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.03. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -8.03, marking a decrease of 2.45.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.95. This value is below the healthy minimum of 5. It has decreased from -5.50 (Mar 24) to -7.95, marking a decrease of 2.45.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.04. This value is below the healthy minimum of 3. It has decreased from -1.57 (Mar 24) to -5.04, marking a decrease of 3.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 48.29 (Mar 24) to 47.81, marking a decrease of 0.48.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 50.97 (Mar 24) to 47.81, marking a decrease of 3.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.68. It has decreased from 96.32 (Mar 24) to 88.68, marking a decrease of 7.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.84. This value is within the healthy range. It has increased from 5.34 (Mar 24) to 11.84, marking an increase of 6.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.45. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 8.45, marking an increase of 7.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from -5.93 (Mar 24) to 2.61, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.44. This value is below the healthy minimum of 2. It has decreased from -6.26 (Mar 24) to -8.44, marking a decrease of 2.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.40. This value is below the healthy minimum of 2. It has decreased from -5.54 (Mar 24) to -7.40, marking a decrease of 1.86.
- For PBDIT Margin (%), as of Mar 25, the value is 13.35. This value is within the healthy range. It has increased from 5.54 (Mar 24) to 13.35, marking an increase of 7.81.
- For PBIT Margin (%), as of Mar 25, the value is 9.52. This value is below the healthy minimum of 10. It has increased from 0.67 (Mar 24) to 9.52, marking an increase of 8.85.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has increased from -6.15 (Mar 24) to 2.94, marking an increase of 9.09.
- For Net Profit Margin (%), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 5. It has decreased from -6.50 (Mar 24) to -9.51, marking a decrease of 3.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -8.34. This value is below the healthy minimum of 8. It has decreased from -5.75 (Mar 24) to -8.34, marking a decrease of 2.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.47. This value is below the healthy minimum of 15. It has decreased from -11.35 (Mar 24) to -15.47, marking a decrease of 4.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 0.89 (Mar 24) to 13.47, marking an increase of 12.58.
- For Return On Assets (%), as of Mar 25, the value is -6.87. This value is below the healthy minimum of 5. It has decreased from -4.75 (Mar 24) to -6.87, marking a decrease of 2.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.29, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has decreased from 0.80 (Mar 24) to 0.71, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.80 (Mar 24) to 0.83, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.40, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.21, marking an increase of 1.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 3. It has increased from 1.48 (Mar 24) to 2.23, marking an increase of 0.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 3. It has increased from 0.08 (Mar 24) to 1.59, marking an increase of 1.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,620.14. It has increased from 2,050.95 (Mar 24) to 3,620.14, marking an increase of 1,569.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.17. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 2.17, marking an increase of 0.90.
- For EV / EBITDA (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 15. It has decreased from 22.92 (Mar 24) to 16.27, marking a decrease of 6.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For Price / BV (X), as of Mar 25, the value is 3.51. This value exceeds the healthy maximum of 3. It has increased from 1.83 (Mar 24) to 3.51, marking an increase of 1.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to -0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camlin Fine Sciences Ltd:
- Net Profit Margin: -9.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.47% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.47% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 182 (Industry average Stock P/E: 74.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -9.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Floor 2 to 5, In GS Point, Mumbai Maharashtra 400098 | secretarial@camlinfs.com https://www.camlinfs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ashish Dandekar | Chairman & Managing Director |
| Mr. Nirmal Momaya | Managing Director |
| Mr. Arjun Dukane | Executive Director -Technical |
| Mr. Joseph Conrad D'souza | Independent Director |
| Ms. Anagha Dandekar | Non Exe.Non Ind.Director |
| Mr. Harsha Raghavan | Non Exe.Non Ind.Director |
| Mr. Jens Van Nieuwenborgh | Non Exe.Non Ind.Director |
| Mr. Mahabaleshwar Palekar | Independent Director |
| Mr. Pradip Kanakia | Independent Director |
| Mr. Amol Shah | Independent Director |
| Ms. Radhika Dudhat | Independent Director |
| Mr. Abeezar Faizullabhoy | Independent Director |
FAQ
What is the intrinsic value of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd's intrinsic value (as of 19 December 2025) is 1053.69 which is 575.44% higher the current market price of 156.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 2,921 Cr. market cap, FY2025-2026 high/low of 335/113, reserves of ₹871 Cr, and liabilities of 2,037 Cr.
What is the Market Cap of Camlin Fine Sciences Ltd?
The Market Cap of Camlin Fine Sciences Ltd is 2,921 Cr..
What is the current Stock Price of Camlin Fine Sciences Ltd as on 19 December 2025?
The current stock price of Camlin Fine Sciences Ltd as on 19 December 2025 is 156.
What is the High / Low of Camlin Fine Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Camlin Fine Sciences Ltd stocks is 335/113.
What is the Stock P/E of Camlin Fine Sciences Ltd?
The Stock P/E of Camlin Fine Sciences Ltd is 182.
What is the Book Value of Camlin Fine Sciences Ltd?
The Book Value of Camlin Fine Sciences Ltd is 47.3.
What is the Dividend Yield of Camlin Fine Sciences Ltd?
The Dividend Yield of Camlin Fine Sciences Ltd is 0.00 %.
What is the ROCE of Camlin Fine Sciences Ltd?
The ROCE of Camlin Fine Sciences Ltd is 11.0 %.
What is the ROE of Camlin Fine Sciences Ltd?
The ROE of Camlin Fine Sciences Ltd is 15.0 %.
What is the Face Value of Camlin Fine Sciences Ltd?
The Face Value of Camlin Fine Sciences Ltd is 1.00.